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ABSTRACT
Purpose: Rheumatoid arthritis (RA) is a destructive inflammatory disease that
commonly involves joints of the hand and wrist. Different recommendations
exist for continuing or discontinuing immunosuppressant medications during
the perioperative time period. The purpose of our study was to determine if
continuing steroids, non-biologic DMARDs, and/or biologic DMARDs were
associated with an increased risk of postoperative complications.
Methods: We performed a single-centered, retrospective review of a
consecutive cohort of RA patients who had elective hand surgery by a single
surgeon. Patients were included if they had a documented diagnosis of
seropositive RA by a rheumatologist, and had elective hand surgery and/or
disease-related surgical procedure involving the upper extremity from January
2008 to August 2018. We stratified patients into different groups for
comparison by classes of immunosuppressant medications for managing RA.
These classes included corticosteroids, non-biological DMARDs, biologic
DMARDs, and/or no medications. Groups were then compared for the
incidence of postoperative complications.
Results: Eighty-eight consecutive patients had elective hand and/or upper
extremity surgeries for RA. Mean patient age at the time of surgery (±SD)
was 55±13 years (range: 24 to 74 years). Of these 88 patients, eight (9%)
overall complications occurred. Complications were wound healing failures,
(n=5, 6%), tendon rupture, (n=1, 1%), hematoma, (n=1, 1%), and surgical site
infection, (n=1, 1%). Perioperative medications included steroids (n=31), nonbiologic DMARDs (n=68), and biologic DMARDs (n=5). There were no
significant findings between patients on perioperative corticosteroids, nonbiologic DMARDs, and/or biologic DMARDs and the incidence of
complications. Mean follow-up was 69±65 weeks (range: 8 to 296 weeks).
Conclusions: Patients with RA who continued corticosteroids, non-biologic
DMARDs, and/or biologic DMARDS within one dosing interval of their usual
dose were not associated with a higher risk for postoperative complications
compared to patients discontinuing these medications perioperatively,
following elective hand surgery.

INTRODUCTION
Rheumatoid arthritis (RA) is the most common chronic destructive
inflammatory disease. Synovial surfaces of the hand and wrist joints are
affected in 70% of patients with RA. 1,2 If untreated, RA progresses to joint
destruction and pain, disability, systemic complications, poor quality of life,
and a decreased lifespan. 1 First-line medication management with
immunosuppressing disease-modifying antirheumatic drugs (DMARDs) has
proven to improve survival and decrease surgical interventions in patients with
RA. 1-3 However, these medications prevent disease progression, and do not
treat already damaged joints. 2,3
As the disease progresses, surgery may be required to decrease pain, correct
deformities, and increase range of motion. 2,4 Prior to any surgical procedure,
many surgeons discontinue immunosuppressant medications to prevent the
complications associated with wound healing and surgical wound infections. 410 Corticosteroids, non-biologic and biologic DMARDs are all classes of
medications with different pharmacologic mechanisms and varying
immunosuppressant activity commonly taken by patients diagnosed with
rheumatoid arthritis to prevent disease progression. 3 Continuing steroids and
non-biologic DMARDs, but holding biologic DMARDs weeks prior to having
hip or knee surgery is currently recommended by the American College of
Rheumatology and American Association of Hip and Knee Surgeons and the
literature. 1,3,11-14 These recommendations include discontinuing etanerept
1week before surgery, infliximab, golimumab, tocilizumab, abatacept,
adalimumab, certolizumab, 4 weeks before surgery, and rituximab 8 weeks
before surgery. 1,3,11-14
We could find no study in the literature that evaluated different combinations
of perioperative immunosuppressant medications in a cohort of rheumatoid
arthritis patients that had elective hand surgery. The primary purpose of our
study was to determine if continuing steroids, non-biologic DMARDS, and/or
biologic DMARDS was associated with increased postoperative
complications. A secondary aim was to see what patient demographic
variables and comorbidities were associated or predictors for developing
specific complications in our patient population.
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MATERIAL AND METHODS
Study design
We performed an Institutional Review Board (IRB#00196757) approved
retrospective medical record review to collect a consecutive cohort of
rheumatoid arthritis patients who had elective hand surgery by a single
surgeon at a single institution. The STROBE checklist was followed
throughout our review.
Study population
Patients were included if they had a documented diagnosis of seropositive
rheumatoid arthritis by a rheumatologist with an International Classification
of Diseases (ICD) 9 code of 714.0 or ICD 10 code of M06.9, and had elective
hand and/or upper extremity surgery between January 2008 to August 2018.
Diagnosis of rheumatoid arthritis was confirmed by a rheumatologist with the
2010 American College of Rheumatology (ACR)/European League Against
Rheumatism (EULAR) classification criteria.
We stratified patients into different groups for comparison by classes of
chronic medications for managing rheumatoid arthritis taken during the
perioperative period. These classes included corticosteroids, non-biological
DMARDs, biologic DMARDs, and/or no medications. Biologic DMARDs
were considered as perioperative medications if the time of surgery was within
one dosing interval of that individual’s standard medication regimen. Groups
were then evaluated for the incidence of postoperative complications and
compared to determine if classes of medications had any association.
Demographic variables
Patient characteristics are summarized in Table 1. These include: mean age,
sex, body mass index (BMI), Race, Ethnicity, employment status, smoking
status (current every day smoker or quit within past 6 months), moderate
alcohol use (≥ 1 drink a day for women, ≥ 2 drinks a day for men), illicit drug
use, comorbidities, and chronic medications to manage rheumatoid arthritis.
Outcomes analyzed
Primary outcomes measured were the number of complications evaluated and
confirmed by a healthcare provider during patient follow-up. Complications
were wound healing failure, tendon rupture, hematoma, surgical site infection,
and overall complications. Non-healing wounds or wound healing failure was
clinically defined as the absence of healthy granulation tissue, presence of
necrotic and unhealthy tissue in the wound bed, excess exudate and slough,
lack of blood supply, re-epithelialization failure, persistent pain, recurrent
breakdown of the wound, or clinical or subclinical infection. Tendon rupture
was defined as the tendon partially or completely separating from tissue to
which it was attached, and confirmed with diagnostic imaging. Hematoma
was defined as a collection of blood within the tissue and confirmed with
diagnostic imaging. Surgical site infection was defined by the Centers for
Disease Control and Prevention (CDC) as an infection occurring at the
surgical site within 30 days of the operation without an implant or within a
year of the operation with an implant. 19 Overall complications were defined
as the sum of all complications occurring in a perioperative medication group.
Statistical analysis
Statistical analysis was performed to compare complications to different
combinations of perioperative rheumatoid arthritis medications. We used the
crosstabulation Fisher’s exact test for categorical complication variables based
on the nonparametric distribution of population data, small sample sizes, and
disproportionate sizes of comparative groups. Bimodal logistic regression was
used to compare patient demographic variables to specific complications to
identify individual predictors for occurrence.

RESULTS
Demographics
Table 1 contains our patient demographics. Eighty-eight consecutive patients
had elective hand and/or upper extremity surgery for seropositive RA over the
ten-year study period (mean age 55±13, range: 24 to 74 years). Surgical
procedures were performed on 42 right upper extremities and 46 left upper
extremities. Fingers were involved in 44 cases, wrists 42 cases, forearms 4
cases, and the elbow in 10 surgical cases. Combinations included 5 cases
involving fingers and wrists, 2 forearms and elbows, 2 wrists and elbows, 1
wrist and forearm, and 3 fingers and elbows. Perioperative medications
included steroids (n=31), non-biologic DMARDs (n=68), and biologic
DMARDs (n=5). Biologic DMARDs continued were adalimumab (n=2)
within two weeks of surgery, abatacept (n=1) within four weeks of surgery,
and tocilizumab (n=2) within one week of surgery. Mean follow-up was
69±65 weeks (range: 8 to 296 weeks).
Wound healing failure
Eight patients developed complications. Five of the eight (63%) complications
were wound healing failures (Table 2). Of these five, one case occurred in a
patient taking steroids and non-biologics, one case occurred in a patient taking
only non-biologics, and three cases occurred in patients on no medications.
There were no significant increased risks of wound healing failure in patients
taking steroids, non-biologic DMARDs, and/or biologic DMARDs during the
perioperative period (p=NS). Following bimodal logistic regression, there
were no significant positive predictors for wound healing failure among our
study demographic variables (p=NS).
Tendon rupture
One of the eight (13%) complications was tendon rupture (Table 2). The
surgery performed preceding was a synovectomy of the left 4th, 5th, and 6th
extensor compartments, resection of left distal ulna, and suspension of the
ulnar shaft using a distally based extensor carpi ulnaris tendon. Three months
following the procedure, magnetic resonance imaging (MRI) confirmed
rupture of the left extensor tendons of fingers 3, 4, and 5. This one case
occurred in a patient taking no medications. The patient stated the ruptured
occurred two months prior from no known inciting event. There were no
significant increased risks of tendon rupture in patients taking no medications,
steroids, non-biologic DMARDs, and/or biologic DMARDs during the
perioperative period (p=NS). Following bimodal logistic regression, there
were no significant positive predictors for tendon rupture among our study
demographic variables (p=NS).
Hematoma
One of the eight (13%) complications was a hematoma (Table 2). This one
case occurred in a patient taking no medications. There were no significant
increased risks of hematoma in patients taking no medications, steroids, nonbiologic DMARDs, and/or biologic DMARDs during the perioperative period
(p=NS). Following bimodal logistic regression, there were no significant
positive predictors for hematoma among our study demographic variables
(p=NS).
Surgical site infection
One of the eight (13%) complications was a surgical site infection (Table 2).
This one case occurred in a patient taking steroids and non-biologics (p=NS).
There were no significant increased risks of surgical site infections in patients
taking steroids, non-biologic DMARDs, and/or biologic DMARDs during the
perioperative period. Following bimodal logistic regression, there were no
significant positive predictors for surgical site infections among our study
demographic variables (p=NS).
Overall complications
There were eight overall complications in 88 (9%) hand surgery cases (Table
2). Two (25%) in patients taking steroids and non-biologics, one (25%) in
patients taking only steroids, and five (63%) in patients taking no medications
(p=NS). There were no significant increased risks of overall complications in
patients taking steroids, non-biologic DMARDs, and/or biologic DMARDs
during the perioperative period. Following bimodal logistic regression, there
were no significant positive predictors for overall complications among our
study demographic variables (p=NS).

CONCLUSION
▪Patients with seropositive
RA who continued
corticosteroids, nonbiologic DMARDs, and/or
biologic DMARDS did not
have a higher occurrence
of postoperative
complications compared to
patients discontinuing
these medications
perioperatively, following
elective hand surgery.
There were no associated
predictors for patients
developing postoperative
complications. Our
findings suggest patients
with RA may be able to
continue medications
during elective hand
surgery. A prospective
randomized controlled trial
should be performed to
validate our study findings.
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